NYSE · Drug Manufacturers - General

ABBV (ABBV) Stock

$260.17 +1.46% NYSE: ABBV Healthcare

Valuation

MetricValue
Price$260.17
Market Cap$459.67B
P/E Ratio74.06
P/B Ratio-78.44
P/S Ratio7.21
EPS (TTM)$2.37
52-Week High$267.47
52-Week Low$190.75
Dividend Yield2.63%

Financials & Margins

MetricValue
ROE-136.50%
ROA4.67%
ROCE20.19%
Gross Margin32.85%
Operating Margin32.85%
Net Margin9.81%
Debt/Equity-11.93
Current Ratio0.67

Annual Financials (USD)

Metric20212022202320242025
Revenue$56.2B$58.1B$54.3B$56.3B$61.2B
Operating Profit$17.9B$18.1B$12.8B$9.1B$20.1B
Net Profit$11.5B$11.8B$4.9B$4.3B$4.2B
EPS$6.45$6.63$2.72$2.39$2.37
Op Margin31.9%31.2%23.5%16.2%32.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$146.5B$138.8B$134.7B$135.2B$134.0B
Total Liabilities$131.1B$121.5B$124.3B$131.8B$137.2B
Cash$9.7B$9.2B$12.8B$5.5B$5.2B
Borrowings$77.6B$64.2B$60.1B$67.8B$69.1B

Latest News

Johnson & Johnson CFO Says This Drug Is Outperforming ‘Almost Any Launch’ in Recent Memory Barrons.com · Jul 15, 2026 Should You Buy, Sell or Hold ABBV Stock After Its 9% YTD Rise? Zacks · Jul 15, 2026 Citigroup Adjusts Price Target on AbbVie to $260 From $230, Maintains Neutral Rating MT Newswires · Jul 15, 2026 AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It Zacks · Jul 15, 2026 AbbVie vs Baxter: One Golden Cross Is Real, One Is a Trap 24/7 Wall St. · Jul 15, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$22.8B$24.9B$22.8B$18.8B$19.0B
Investing Cash Flow$-3.1B$-1.3B$-2.8B$-21.8B$-7.9B
Financing Cash Flow$-1.4B$-2.3B$-2.5B$-1.5B$-912.0M
Net Cash Flow$1.3B$-545.0M$3.6B$-7.3B$-295.0M
Free Cash Flow$22.0B$24.2B$22.1B$17.8B$17.8B

Valuation & Return Ratios

MetricValue
PEG Ratio1.09
EV / EBITDA24.90
FCF Yield4.24%
Quick Ratio0.69
Interest Coverage6.47
Return 1Y26.69%
Return 3Y92.00%
Return 5Y163.58%

Ownership

Insiders Held0.11%
Institutions Held76.85%
Institutions Float Held76.93%
Institutional HolderSharesReport Date
Blackrock Inc.150,698,1252026-03-31
Vanguard Capital Management LLC114,880,3242026-03-31
State Street Corporation81,217,5162026-03-31
JPMORGAN CHASE & CO56,741,6912026-03-31
Vanguard Portfolio Management LLC49,523,0782026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AMGN $435.89 +1.40% 27.15 $235.25B 2.29%
AZN $161.96 -0.10% 24.78 $251.18B 1.28%
GILD $148.94 +1.78% -56.96 $184.92B 2.21%
JNJ $270.47 +1.74% 31.21 $651.81B 1.99%
MRK $149.59 +1.24% 121.55 $369.46B 2.22%

About ABBV

ABBV is led by CEO Robert A. Michael, employs 55,000 people, headquartered in North Chicago, US, publicly traded since 2013.

ABBV stock trades at $260.17 with a market capitalization of $459.67B. The stock is valued at a price-to-earnings (P/E) ratio of 74.06, price-to-book of -78.44, price-to-sales of 7.21. Over the past 52 weeks the stock has ranged between $190.75 and $267.47, and currently trades 2.7% below its 52-week high. It pays a dividend yielding 2.63%.

On profitability, ABBV generates a return on equity (ROE) of -136.50%, return on capital employed of 20.19%, an operating margin of 32.85%, a net profit margin of 9.81%.

In its most recent fiscal year, ABBV reported annual revenue of $61.2B, net profit of $4.2B, revenue has compounded at 6.0% a year over the last five years, profit at -1.7% a year.

The balance sheet shows a debt-to-equity ratio of -11.93 — a conservative balance sheet with little leverage risk, a current ratio of 0.67, total assets of $134.0B, $5.2B in cash and equivalents.

ABBV has a beta of 0.28 (less volatile than the overall market).

Related Healthcare Stocks

LLY Drug Manufacturers - General $1161.39 +0.40% JNJ Drug Manufacturers - General $270.47 +1.74% MRK Drug Manufacturers - General $149.59 +1.24% UNH Medical - Healthcare Plans $396.10 +1.72% NVS Drug Manufacturers - General $161.48 +6.19% AZN Drug Manufacturers - General $161.96 -0.10% AMGN Drug Manufacturers - General $435.89 +1.40% TMO Medical - Diagnostics & Research $601.51 -2.53% NVO Biotechnology $45.17 -0.35% ABT Medical - Devices $109.49 -0.79% GILD Drug Manufacturers - General $148.94 +1.78% PFE Drug Manufacturers - General $28.49 +0.09%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNYSE High ROE StocksAll stock screens
Run Stock Screener Investing Guides